Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seer, Inc.SEER · Entity 6717 | Director | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seer, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 53,375 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 12,375 · Balance 53,375 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2036-07-28 | Direct | 18,750 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 18,750 · Balance 18,750 F2: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
F2: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GeneDx Holdings Corp.
Report date July 01, 2022 · Filed May 31, 2023
Section 16 reporting ended · disclosed 2023-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 206,886 |
Ending reported balance
After 2022-07-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-01 · Exercise / conversion · Acquired 7,396 · Balance 209,182 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Row 2 · 2022-07-05 · Sale · Disposed 2,296 · Balance 206,886 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 110,954 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Exercise / conversion · Disposed 7,396 · Balance 110,954 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:27 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001873463-26-000002 · form4-07302026_080726.xml · derivative · entry 2 Ro Isaac · CIK 0001873463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Class A Common Stock · 18,750 shares Expires 2036-07-28 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:27 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 12,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001873463-26-000002 · form4-07302026_080726.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,375 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 01:06 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 61,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-25-023618 · form4-09042025_010927.xml · derivative · entry 2 Ro Isaac · CIK 0001873463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,000 Underlying: Class A Common Stock · 61,000 shares Expires 2035-09-02 F2 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on September 2, 2026. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 01:06 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023618 · form4-09042025_010927.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in three equal annual installments beginning on September 2, 2026. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 23:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 20,245 | $1.99 | $40,216.69 |
DisclosureSEC source: 0001209191-22-045315 · doc4.xml · nonDerivative · entry 2 Ro Isaac · CIK 0001873463 · Former CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,041 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.89 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 23:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045315 · doc4.xml · derivative · entry 3 Ro Isaac · CIK 0001873463 · Former CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Class A Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 23:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-045315 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Former CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 05, 2022 Filed May 31, 2023 20:19 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,296 | $1.32 | $3,027.74 |
DisclosureSEC source: 0001209191-23-033109 · doc4.xml · nonDerivative · entry 2 Ro Isaac · CIK 0001873463 · Former CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,886 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2022 Filed May 31, 2023 20:19 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 7,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033109 · doc4.xml · derivative · entry 3 Ro Isaac · CIK 0001873463 · Former CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,954 Underlying: Class A Common Stock · 7,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed May 31, 2023 20:19 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 7,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033109 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Former CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:22 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 19,515 | $2.46 | $48,006.90 |
DisclosureSEC source: 0001209191-22-028689 · doc4.xml · nonDerivative · entry 2 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,786 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| May 08, 2022 Filed May 13, 2022 00:22 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028689 · doc4.xml · derivative · entry 3 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,500 Underlying: Class A Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| May 08, 2022 Filed May 13, 2022 00:22 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028689 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 21:08 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 1,284 | $2.91 | $3,736.57 |
DisclosureSEC source: 0001209191-22-023878 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,801 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover certain tax obligation in connection with the stock bonus granted to the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.91 to $2.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:16 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 118,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023517 · doc4.xml · derivative · entry 3 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,350 Underlying: Class A Common Stock · 118,350 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:16 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 205,469 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-22-023517 · doc4.xml · derivative · entry 2 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,469 Underlying: Class A Common Stock · 205,469 shares Expires 2032-04-03 F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:16 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantClass A Common Stock | 3,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023517 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,085 F1 · shares: The indicated shares were issued to the Reporting Person as a stock bonus. The stock bonus was fully-vested as of the date of issuance. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 01:30 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 21,735 | $3.60 | $78,241.65 |
DisclosureSEC source: 0001209191-22-008637 · doc4.xml · nonDerivative · entry 2 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,189 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 01:30 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008637 · doc4.xml · derivative · entry 3 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Class A Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 01:30 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-008637 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:08 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 197,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069330 · doc4.xml · derivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,607 Underlying: Class A Common Stock · 197,607 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2 · derivative.exercise_price: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F3 · derivative.exercise_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 24,701 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 14 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. F3 · derivative.expiration_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 24,701 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 14 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:56 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Tax withholdingClass A Common Stock | 215 | $5.52 | $1,186.80 |
DisclosureSEC source: 0001209191-21-067986 · doc4.xml · nonDerivative · entry 2 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,424 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover certain tax obligation in connection with the stock bonus granted to the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:56 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantClass A Common Stock | 618 | $6.05 | $3,738.90 |
DisclosureSEC source: 0001209191-21-067986 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,639 F1 · shares: The indicated shares were issued to Reporting Person as a stock bonus in connection with the elimination of Issuer's sabbatical leave program, in which all employees of Issuer hired on or before June 30, 2021 were provided an opportunity to receive a stock bonus in lieu of their continued eligibility to take sabbatical leave. The stock bonus was fully vested as of the date of issuance. Read SEC document |
| November 29, 2021 Filed Dec 2, 2021 01:08 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 12,115 | $6.63 | $80,322.45 |
DisclosureSEC source: 0001209191-21-067376 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,021 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.59 to $6.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 23:54 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-063952 · doc4.xml · derivative · entry 3 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812,500 Underlying: Class A Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 23:54 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 19,516 | $8.49 | $165,694.74 |
DisclosureSEC source: 0001209191-21-063952 · doc4.xml · nonDerivative · entry 2 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,136 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 23:54 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 62,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-063952 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062549 · doc4.xml · derivative · entry 3 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Underlying: Class A Common Stock · 125,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vest on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 1/8th of the total shares vested on October 25, 2021, 1/16th of the total shares vest on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 40,848 | $7.54 | $307,993.92 |
DisclosureSEC source: 0001209191-21-062549 · doc4.xml · nonDerivative · entry 2 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,152 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-062549 · doc4.xml · nonDerivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 01:43 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059756 · doc4.xml · derivative · entry 2 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: 1/8th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: 1/8th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 01:43 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 578,704 | $0.00 Strike: $7.62 | $0.00 |
DisclosureSEC source: 0001209191-21-059756 · doc4.xml · derivative · entry 1 Ro Isaac · CIK 0001873463 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,704 Underlying: Class A Common Stock · 578,704 shares Expires 2031-09-30 F1 · derivative.exercise_date: 1/8th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.